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CRISPR-LbCpf1 prevents choroidal
neovascularization in a mouse model of age-related
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Taeyoung Koo1,2, Sung Wook Park 3,4,5, Dong Hyun Jo 3, Daesik Kim6, Jin Hyoung Kim3, Hee-Yeon Cho1,
Jeungeun Kim6, Jeong Hun Kim3,4,5 & Jin-Soo Kim1,2,6
LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonu-
clease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used
for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD).
The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding
vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using
adeno-associated virus, led to efﬁcient gene disruption with no apparent off-target effects in
the retina and retinal pigment epithelium (RPE) cells. Importantly, LbCpf1 targeted to Vegfa or
Hif1a in RPE cells reduced the area of laser-induced choroidal neovascularization as efﬁciently
as aﬂibercept, an anti-VEGF drug currently used in the clinic, without inducing cone
dysfunction. Unlike aﬂibercept, LbCpf1 targeted to Vegfa or Hif1a achieved a long-term
therapeutic effect on CNV, potentially avoiding repetitive injections. Taken together,
these results indicate that LbCpf1-mediated in vivo genome editing to ablate pathologic
angiogenesis provides an effective strategy for the treatment of AMD and other
neovascularization-associated diseases.
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Wet age-related macular degeneration (AMD), aneovascular disease that leads to vision loss in thecenter of the visual ﬁeld, occurs most commonly in
individuals over the age of 501. Several angiogenic growth factors
in the retina have been implicated, including vascular endothelial
growth factor (VEGF)2. The advent of anti-VEGF agents
(e.g., aﬂibercept, bevacizumab, and ranibizumab) has led to
signiﬁcantly reduced retinal and choroidal neovascularizations
(CNV) in the clinic3,4. However, currently used anti-VEGF
therapies require frequent repetitive injections over time to
sustain the therapeutic effect on ocular neovascularization5–7.
Therefore, it is ideal to suppress pathologic angiogenesis with a
single treatment over the long-term.
The type II CRISPR (clustered regularly interspaced short
palindromic repeats) system, an adaptive immune system used by
bacteria and archaea to defend against viral infection8, has been
repurposed for site-speciﬁc genome modiﬁcation9–12 and become a
promising approach for the treatment of diverse genetic or non-
genetic disorders13–16. The Cas9 protein (SpCas9), derived from
Streptococcus pyogenes, in combination with a small-guide RNA
(sgRNA), a synthetic fusion of CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA)17, recognizes and cleaves a target
locus, generating a blunt-ended double-stranded break (DSB) three
nucleotides upstream of a protospacer adjacent motif (PAM).
However, the relatively large size of the SpCas9-coding sequence
(4.10 kbp encoding 1,368 amino acids) makes it difﬁcult or
impossible to package the system with a sgRNA expression cassette
into an adeno-associated virus (AAV). Furthermore, concerns
remain about SpCas9 off-target nuclease activity. These issues have
accelerated efforts to develop alternative genome editing tools.
A recently reported RNA-guided endonuclease, CRISPR from
Prevoltella and Francisella 1 (Cpf1), is derived from a type V
(class II) CRISPR system and differs from Cas9 in several key
respects18. Cpf1 is guided by a single crRNA, without the need for
a tracrRNA18. In contrast to Cas9, Cpf1 exhibits ribonuclease
activity, enabling it to process its precursor crRNA into mature
crRNAs19. Cpf1 recognizes a T-rich PAM (5′-TTTV-3′) at the
5′- end of a protospacer; DNA cleavage generates a staggered DSB
distal to the PAM site20. It has been reported that LbCpf1 from
Lachnospiraceae bacterium ND 2006 and AsCpf1 from Acid-
aminococcus sp. BV3L6 induce DNA modiﬁcations in human
cells with equal or greater efﬁciency than do Cas9 orthologues,
including SaCas9, StCas9, and NmCas9 from Staphylococcus
aureus, Streptococcus thermophilus, and Neisseria meningitidis,
respectively21. In addition, there are several reports demonstrat-
ing that LbCpf1 exhibits a higher genome-wide speciﬁcity
compared to SpCas922,23.
To test whether LbCpf1 can be used as a gene therapy tool for
the treatment of retinal diseases with the advantage of a smaller
gene size (3.7 kbp encoding 1,299 amino acids) compared to
SpCas9, we packaged sequences encoding LbCpf1 and its crRNA
(total transgene cassette size; 4.7 kbp) in all-in-one AAV vector
and delivered the resulting AAV into the mouse retina via
intravitreal injection. We found that insertions and deletions
(indels), a measure of Cpf1 activity, were induced at high fre-
quencies in the Vegfa and Hif1a genes with target speciﬁcity. In
particular, Vegfa or Hif1a disruption led to a long-term reduction
of the area of laser-induced CNV without causing cone dys-
function. These ﬁndings suggest that Cpf1 has great potential as
an in vivo genome editing therapy for the treatment of
angiogenesis-related diseases.
Results
CRISPR-LbCpf1-mediated gene editing in vitro and in vivo. To
evaluate LbCpf1-mediated genome editing of angiogenesis-
associated genes, we designed several crRNAs to target Vegfa or
Hif1a exons. Cpf1 nucleases complexed with these crRNAs
induced indels at frequencies that ranged from 1.1 ± 0.1% to 24.5
± 0.4% in C2C12 mouse myotubes (Fig. 1a; Supplementary
Table 1). We selected the TS3 and TS3 crRNAs, which target the
exon 1 of Vegfa and exon 8 of Hif1a genes, respectively (Fig. 1b),
because they both resulted in high ratio of out-of-frame indels as
a representative mutation pattern with high efﬁciencies (Fig. 1a;
Supplementary Fig. 1).
To investigate the genome editing efﬁciency of LbCpf1 in the
mouse retina, we expressed Cpf1 with Vegfa (TS3) or Hif1a (TS3)
speciﬁc crRNA in a single AAV vector plasmid (Fig. 1c). Cpf1
induced indels at frequencies of 14.5 ± 0.7% and 12.5 ± 0.2%,
respectively in C2C12 mouse myotubes (Fig. 1c). Then, we
packaged sequences encoding LbCpf1 and Vegfa- or Hif1a-speciﬁc
crRNA into an AAV serotype 9 vector. The resulting viruses were
administered into the mouse eye via intravitreal injection. AAV2/9
expressing Vegfa-speciﬁc LbCpf1 (AAV-Cpf1-Vegfa) induced
indels with frequencies of 57.2 ± 4.1% and 6.5 ± 2% in the retina
and RPE, respectively, 6 weeks post-injection (Fig. 1d). Analysis of
indel-bearing sequences showed that 86 ± 0.9% and 93 ± 2.9%
carried out-of-frame mutations induced by LbCpf1 in the retina
and RPE, respectively (Fig. 1d; Supplementary Fig. 2). AAV2/9
expressing Hif1a-speciﬁc LbCpf1 (AAV-Cpf1-Hif1a) induced
indels with frequencies of 59.2 ± 4.9% and 17.2 ± 5.3% in the
retina and RPE, respectively, 6 weeks post-injection (Fig. 1e).
Analysis of indel-bearing sequences showed that 90 ± 0.4% and 92
± 0.6% carried out-of-frame mutations in the retina and RPE,
respectively (Fig. 1e; Supplementary Fig. 2). As expected, an HA
tag conjugated to the C-terminus of LbCpf1 was detected in both
retina and RPE cells, indicating that LbCpf1 was successfully
expressed (Supplementary Figs. 3, 4).
We compared indel frequencies at the Hif1a target site at 4 and
6 weeks after intravitreal injection of AAV9-Cpf1-Hif1a.
We observed an increase in indel frequencies from 3.7 ± 1.6%
to 17.2 ± 5.3% in RPE cells but did not observe an increase in the
retina (Supplementary Fig. 5).
Target speciﬁcity of LbCpf1 in the mouse retina. We next
investigated whether LbCpf1 has off-target nuclease activity in the
mouse eye. To determine the genome-wide speciﬁcity of the
Vegfa-or Hif1a-targeting LbCpf1 nuclease, we ﬁrst carried out
nuclease-digested whole genome sequencing (Digenome-seq).
Cell-free mouse genomic DNA was digested in vitro using the
Vegfa- or Hif1a-targeting LbCpf1 ribonucleoprotein (RNP)
complex and then subjected to whole genome sequencing (WGS)
(Fig. 2). The Vegfa- or Hif1a-targeting LbCpf1 cleaved two sites or
one site, respectively, including the on-target site, in the mouse
genome (Fig. 2a, b; Supplementary Table 2). These results are in
line with previous reports showing the high speciﬁcity of Cpf1 in
the human or mouse genome22–24. Next, we performed targeted
deep sequencing at the Digenome-seq captured off-target site
using genomic DNA isolated from AAV-Cpf1-Vegfa edited mouse
retina and RPE. No off-target indels were detectably induced in
RPE (Fig. 2c; Supplementary Table 3). In the Cpf1 edited retina,
off-target indels were detected with a frequency of 0.17 ± 0.02%.
We additionally analyzed 1 potential off-target site in the mouse
genome, which differed from the Vegfa or Hif1a on-target site by
up to four nucleotides in AAV-Cpf1-Vegfa or -Hif1a treated retina
and RPE. Potential sites were identiﬁed using the Cas-OFFinder
program. No off-target indels were detectably induced in
AAV-Cpf1-Vegfa or -Hif1a injected mouse retina or RPE cells
(Supplementary Fig. 6; Supplementary Table 4). Taken together,
these results show that the LbCpf1 nuclease is targeted to Vegfa or
Hif1a in the mouse retina in a highly speciﬁc manner in vivo.
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Fig. 1 Genome editing with LbCpf1 in vitro and in vivo. aMutation frequencies at the Vegfa and Hif1a target sites in C2C12 cells co-transfected with various
crRNAs and LbCpf1 genome editing efﬁciencies were examined by deep sequencing using genome DNA isolated from cells after 48 h of transfection. Error
bars indicate s.e.m. (n= 3). b The Cpf1 target sequences in the Vegfa and Hif1a genes. The PAM sequence and the crRNA target sequence (TS3) are shown
in blue and red, respectively. c All-in-one AAV vector plasmids encoding Cpf1 and its crRNA (TS3) and its mutation frequencies at the Vegfa and Hif1a
target sites in C2C12 cells transfected with pAAV-Cpf1-Vegfa or Hif1a plasmids 48 h post-transfection. d,e Indel frequencies and mutant sequences
presented with two fractions, in-frame versus out-of-frame indels at the Vegfa (d) or Hif1a (e) target site in the retina and RPE cells using deep sequencing
6 weeks post-intravitreal injection of AAV-Cpf1-Vegfa or AAV-Cpf1-Hif1a. The PAM sequence and the crRNA target sequence (TS3) are shown in blue and
red, respectively. Error bars indicate s.e.m. (n= 4)
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Therapeutic genome editing for the treatment of CNV. Next,
we induced CNV in the eye by laser treatment 6 weeks after
injection of AAV-Cpf1-Vegfa or -Hif1a and measured the area of
CNV25 1 week later (Fig. 3a). AAV-Cpf1-Vegfa or -Hif1a reduced
the area of CNV by 42 ± 4% and 34 ± 5%, respectively, compared
to the AAV-uninjected negative control (Fig. 3b). A DNMT-spe-
ciﬁc Cpf122, used as another negative control, which expresses
crRNA but does not induce double strand breaks, also did not
show any therapeutic effect. Additionally, we found that AAV-
Cpf1-Vegfa or -Hif1a reduced VEGFA protein levels in the RPE
by 17 ± 3 pg/mg and 15 ± 2 pg/mg, respectively, compared to the
AAV-uninjected negative control (Fig. 3c). In contrast, the
VEGFA protein levels in the retina were not signiﬁcantly different
among groups (Fig. 3c). These data imply that the decrease in the
level of VEGFAprotein in the RPE might be linked to the decrease
in the CNV area. When aﬂibercept, a widely-used anti-VEGF
drug, was injected the same day as the laser treatment, it reduced
the area of CNV by 39 ± 6% relative to the AAV-uninjected
negative control, comparable to the therapeutic effect observed
with injection of AAV-Cpf1-Vegfa or -Hif1a (Fig. 3a, b). However,
when aﬂibercept was injected 6 weeks before the laser treatment,
the area of CNV was not reduced (Fig. 3d, e), in line with the short
half-life of the drug26. This result suggests that genome editing has
a long-term therapeutic effect, whereas aﬂibercept must be injec-
ted multiple times to maintain its therapeutic effect on CNV.
No retinal dysfunction after injection of AAV-Cpf1-Vegfa or
-Hif1a. The conditional knockout of the Vegfa gene in mouse
RPE cells leads to cone dysfunction27. To evaluate the potential
toxicity of AAV-Cpf1-mediated Vegfa or Hif1a gene disruption,
we ﬁrst performed full-ﬁeld electroretinography (ERG) in mice at
6 weeks after the intravitreal injection of AAV-Cpf1-Vegfa or
-Hif1a. We observed no signiﬁcant decrease in the scotopic
response in these mice compared to that in untreated mice
(Fig. 4a, b; Supplementary Fig. 7). In addition, there was no
signiﬁcant change in the photopic response (Fig. 4c; Supple-
mentary Fig. 7). Then, we evaluated the level of opsin expression
in the retina at 6 months after the intravitreal injection of AAV-
Cpf1-Vegfa or -Hif1a. We also found that AAV-Cpf1-Vegfa or
-Hif1a did not affect the size of the opsin-positive area in the
retina, which is closely related to cone function (Fig. 4d, e),
suggesting that AAV-Cpf1-mediated Vegfa or Hif1a gene dis-
ruption provides a safe therapeutic window.
Discussion
In this report, we have shown that LbCpf1 can be successfully
delivered to the mouse retina via an AAV serotype 9 vector and
that it can induce efﬁcient gene editing in the retina and RPE cells.
LbCpf1 induced indels at high frequencies in the Vegfa and Hif1a
genes, suggesting its potential for the treatment of angiogenesis-
associated diseases. Cpf1 has several beneﬁts for therapeutic
applications. First, Cpf1 is highly speciﬁc in human cells with
minimum off-target activities, compared to SpCas9 as shown in
previous reports22,23. The use of Cpf1 also allows for streamlined
multiplex genome editing. Because Cpf1 can process pre-crRNA
arrays, multiple pre-crRNAs can be expressed from a single U6
promoter without the need for additional sequences19,28.
In vivo therapeutic genome editing is an active area of research.
However, unlike ex vivo approaches, in vivo genome editing is
limited by potential immune responses against Cas9 or Cpf1 and
relatively poor efﬁciency of transgene delivery. In this regard, the
eye is an ideal organ for in vivo therapeutic editing because it is
immune-privileged. AAV vectors are powerful tools for delivering
the genome engineering machinery to the ocular tissues29–31.
Indeed, a number of studies have demonstrated efﬁcient expres-
sion of transgenes using AAV serotype 9 in the mouse retina32–35.
In our previous study, we also showed that Cas9 derived from
Campylobacter jejuni is efﬁciently expressed in the retina and
RPE cells after intravitreal injection via an AAV9 vector35. In this
study, we used AAV serotype 9 as a vehicle to deliver Cpf1 and
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crRNA into mouse retina. In contrast to AAV serotype 2, which
targets RPE cells only when delivered by subretinal injection,
AAV9 was efﬁciently transfected into RPE cells after intravitreal
injection35.
AAV-mediated genome editing may cause systemic side effects
if AAV passes through the bloodstream during intravitreal
injection. However, several reports support the safety of AAV in
the treatment of retinal diseases. In LCA clinical trials, there was
no evidence of systemic dissemination of AAV vectors in tears,
serum, or saliva samples 30 days after subretinal administration
of AAV2/2-hRPE6536–38. Sugano et al. and Shih et al. also
assessed the presence of AAV following intravitreal injection:
AAV was detected within the ocular tissues but not in other
organs39,40. However, a study of the immune response to
Cpf1 should also be investigated.
When delivered to the retina and RPE, AAV-Cpf1-Vegfa or
Hif1a induced Vegfa or Hif1a gene disruption, respectively
followed by reduction of the CNV area in a mouse model of
AMD. Its anti-angiogenic effect was comparable to that of aﬂi-
bercept. Note, however, that unlike AAV-Cpf1-Vegfa or Hif1a,
aﬂibercept did not inhibit neovascularization and did not reduce
the area of CNV when given 6 weeks before the laser treatment,
conﬁrming its short half-life in vivo26. This ﬁnding suggests that
AAV-LbCpf1 has a long-term therapeutic effect even with a
single administration and could replace anti-VEGF drugs
currently in use in the clinic. Note that aﬂibercept and other
anti-VEGF drugs must be administered repetitively, often for a
lifetime. Evidence of long-term expression of sequences delivered
by AAV is supported by several promising, ongoing clinical trials
using AAV vectors for retinal disorders41. It has also been
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reported that AAV-mediated transgene expression continued in
non-human primates for as long as 5.5 years after gene transfer
without any detectable toxicity42. The ability of AAV vectors to
mediate long-term transgene expression offers a means of treating
life-long chronic diseases such as AMD with a single adminis-
tration of vector. As such, the use of AAV-Cpf1 may reduce the
cost burden of treatment for patients and improve the quality of
life. Our results support that application of AAV-LbCpf1 as a
gene editing tool will be an effective strategy for treating AMD
and other diseases associated with neovascularization.
Methods
Construction of an AAV vector plasmid encoding LbCpf1 and crRNA. A human
codon-optimized LbCpf1 coding sequence, derived from Lachnospiraceae bacter-
ium ND 2006, was purchased from Addgene (plasmid # 78744). The sequence was
cloned into an AAV inverted terminal repeat (ITR)-based vector plasmid. The
Vegfa, HIf1a, or DNMT targeting crRNA sequence (Supplementary Table 1) was
also inserted to create pAAV-ITR-LbCpf1-crRNA. crRNAs were transcribed under
the control of the U6 promoter and LbCpf1 expression was controlled by the
elongation factor-1 alpha short (EFS) promoter in C2C12 (ATCC, CRL-1772) cells
and in the mouse retina and RPE.
Cell culture and mutation analysis. Cells were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM, Welgene, cat. no. LM001-05) supplemented with 100
units per ml penicillin (Gibco, cat. no. 15140–122), 100 μg/ml streptomycin, and
10% fetal bovine serum heat-inactivated (FBS, Welgene, cat. no. S 101–01). In this
study, we investigated the efﬁcacy of several crRNAs in C2C12 cells because these
cells are efﬁciently transfected. Cells (1 × 105) were seeded into 24-well plates one
day prior to transfection and transfected with the crRNA plasmid (1500 ng) and the
Cpf1 plasmid (500 ng) using 4 μl of Lipofectamine 2000 (Invitrogen, cat. no.
11668019). Cells were maintained in DMEM supplemented with 2% FBS for dif-
ferentiation. Genomic DNA was isolated using a DNeasy Blood & Tissue kit
(Qiagen, cat. no. 69581) 48 h post-transfection. On-target or off-target loci were
ampliﬁed using 100 ng of genomic DNA for targeted deep sequencing. Deep-
sequencing libraries were generated by PCR. TruSeq HT Dual Index primers were
used to label each sample. Pooled libraries were subjected to paired-end sequencing
using MiniSeq (Illumina). Indel frequencies are described in Supplementary Table 1.
Production and titration of AAV vectors. To produce AAV vectors, they were
pseudotyped in AAV9 capsids. HEK293T cells (ATCC, CRL-3216) were trans-
fected with pAAV-ITR-LbCpf1-crRNA, pAAV2/9 encoding for AAV2rep and
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Fig. 4 LbCpf1 targeted to Vegfa or Hif1a does not affect cone function. a–c At day 42 post-AAV injection, full-ﬁeld ERG was performed to evaluate retinal
function. There was no signiﬁcant decrease in the a scotopic a wave, b scotopic b wave, or c photopic response in mice treated with AAV-Cpf1-Vegfa or
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day 42 post-injection. d Relative opsin-positive areas of the AAV-Cpf1-injected mice were normalized to that of the AAV-uninjected negative control mice.
Error bars indicate s.e.m. (n= 4). Student’s t-test. ns not signiﬁcant. e Representative images of opsin positive areas in mice treated with AAV-Cpf1-Vegfa
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AAV9cap, and helper plasmid. HEK293T cells were cultured in DMEM with 2%
FBS. Recombinant pseudotyped AAV vector stocks were generated using PEI
coprecipitation with PEIpro (Polyplus-transfection) and triple-transfection with
plasmids at a molar ratio of 1:1:1 in HEK293T cells. After 72 h of incubation, cells
were lysed and particles were puriﬁed by iodixanol (Sigma-Aldrich) step-gradient
ultracentrifugation. The number of vector genomes was determined by quantitative
PCR.
Digenome sequencing. Genomic DNA was isolated from liver tissue of C57BL/6
mice using a DNeasy Blood & Tissue kit (Qiagen) according to the manufacturer’s
instructions. Genomic DNA (8 μg) was mixed with LbCpf1 protein (300 nM) and
crRNA (900 nM) in a 400 μl reaction buffer (100 mM NaCl, 50 mM Tris-HCl, 10
mM MgCl2, and 100 μg/ml BSA) and the mixture was incubated for 8 h at 37 °C.
Digested genomic DNA was then incubated with RNase A (50 μg/ml) for 30min at
37 °C to degrade crRNAs and puriﬁed again with a DNeasy Blood & Tissue kit
(Qiagen). Digested DNA was fragmented using the Covaris system and ligated with
adapters for library formation. DNA libraries were subjected to whole-genome
sequencing using an Illumina HiSeq X Ten Sequencer at Macrogen (South Korea)
43,44. We used the Isaac aligner to generate a Bam ﬁle using the following parameters:
ver. 01.14.03.12; Mouse genome reference, mm10 from UCSC; Base quality cutoff,
15; Keep duplicate reads, yes; Variable read length support, yes; Realign gaps, no; and
Adapter clipping, yes (adapter: AGATCGGAAGAGC*, *GCTCTTCCGATCT)45. A
DNA cleavage score was assigned to each nucleotide position across the entire
genome, using WGS data, according to the equation presented in Kim et al22. These
equations assume that Cpf1 produces 5′ 1- to 5-nt overhangs. In vitro cleavage sites
with DNA cleavage scores above the cut-off value of 2.5 were computationally
identiﬁed.
Animals. The care, use, and treatment of all animals in this study were in strict
agreement with the ARVO statement for the Use of Animals in Ophthalmic and
Vision Research, the College of Veterinary Medicine guidelines, and the guidelines
established by the Seoul National University Institutional Animal Care and Use
Committee, which granted permission to perform animal experiments. Eight-
week-old, male, speciﬁc pathogen-free C57BL/6 J mice (n= 4–9) were used in this
study. Mice were maintained under a 12 h dark-light cycle.
Laser-induced CNV model. After mice were anesthetized, pupils were dilated with
an eye drop containing phenylephrine (0.5%) and tropicamide (0.5%). Laser
photocoagulation was performed using an indirect head set delivery system (Iridex)
and laser system (Ilooda). Laser parameters were 810 nm wave length, 200 μm spot
size, 800 mW power, and 70 ms exposure time. Laser burn was induced 3–4 times
around the optic disc. Only burns that produced a bubble without vitreous
hemorrhage were included in the study. Seven days later, the eyes were ﬁxed in 4%
paraformaldehyde for 1 h at room temperature. RPE complexes (RPE/choroid/
sclera) were prepared for immunostaining and then incubated with isolectin-B4
(Thermo Fisher Scientiﬁc, cat. no. I21413, 1:100) overnight at 4 °C. The RPE
complex was ﬂat-mounted and viewed with a ﬂuorescent microscope (Eclipse 90i,
Nikon) or a confocal microscope (LSM 710, Carl Zeiss) at a magniﬁcation of 100×.
The CNV area was measured using Image J software (1.47 v, NIH) by blinded
observers. An average of 3–4 CNV areas per eye were analyzed.
Intravitreal injection of AAV. Eight-week-old mice were anesthetized with an
intraperitoneal injection of a mixture of tiletamine and zolazepam (1:1, 2.25 mg/kg
body weight) and xylazine hydrochloride (0.7 mg/kg body weight). AAV2/9-
LbCpf1-Vegfa or -Hif1a (2 × 1010 viral genomes in 2 μl) was intravitreally injected
using a Nanoﬁl syringe with a 33 G blunt needle (World Precision Instruments
Inc.) under an operating microscope (Leica Microsystems Ltd.). The virus dose
used in this study was limited due to production issues, and higher virus doses may
elicit higher mutation efﬁcacy.
Immunoﬂuorescent staining and imaging of retinal tissue. For the analysis of
the opsin-positive area, formalin-ﬁxed parafﬁn embedded samples were prepared
at day 42 post-injection (n= 4). Cross-section samples were immunostained with
anti-opsin antibody (Millipore, cat. no. AB5405, 1:1000) and Alexa Fluor 488
antibody (Thermo Fisher Scientiﬁc, cat. no. A-11034, 1:500). The opsin-positive
area was measured using Image J software (1.47 v, NIH) by blinded observers. To
visualize the distribution of HA-tagged Cpf1, the eyes were ﬁxed in 4% paraf-
ormaldehyde for 1 h at room temperature. RPE complexes (RPE/choroid/sclera)
were prepared for immunostaining and then incubated with anti-HA antibody
(Roche, cat. no. 3F10, 1:100) overnight at 4 °C. After staining with Alexa Fluor 594
antibodies (Thermo Fisher Scientiﬁc, cat. no. A-11006, 1:500), the RPE ﬂat-mounts
were imaged using a confocal microscope (LSM 710, Carl Zeiss). The scanning
parameters were as follows: scaling (x= 0.042 μm/pixel, y= 0.042 μm/pixel, z=
0.603 μm/pixel), dimensions (x= 1024, y= 1024, channels: 2, 8-bit) with objective
C-Apochromat 40 × /1.20W Korr M27. ZEN 2 software was used to process the
images.
Mouse VEGFA ELISA. At day 42 post-injection of AAV2/9-LbCpf1, mice were
treated with laser. Three days after laser treatment, whole RPE complexes were
separated from neural retina tissue and frozen for further analysis. Sample tissues
were lysed in RIPA buffer (120 μl) and Vegfa protein levels were measured using a
mouse VEGF Quantikine ELISA kit (R&D systems, cat. no. MMV00) according to
the manufacturer’s instructions.
Electroretinography (ERG) analysis. Mice were dark-adapted over 16 h. Mice
were anesthetized with an intraperitoneal injection of a mixture of tiletamine and
zolazepam (1:1, 2.25 mg/kg body weight) and xylazine hydrochloride (0.7 mg/kg
body weight). Pupils were dilated with an eye drop containing phenylephrine
(0.5%) and tropicamide (0.5%). Contact lens electrodes were placed on both eyes
with a drop of methylcellulose. Full-ﬁeld ERGs were recorded46 by using the
universal testing and electrophysiologic system 2000 (UTAS E-2000, LKC Tech-
nologies). The responses were recorded at a gain of 2 k using a notch ﬁlter at 60 Hz,
and were bandpass ﬁltered between 0.1 and 1500 Hz. In the light-adapted photopic
state, with a 30 cd/m2 background light to desensitize the rods and isolate cones,
photopic cone responses were recorded in response to a single ﬂash of 0 dB. The
amplitude of the a-wave was measured from the baseline to the lowest negative-
going voltage, whereas peak b-wave amplitudes were measured from the trough of
the a-wave to the highest peak of the positive b-wave.
Statistical analysis. No statistical methods were used to predetermine sample size
for in vitro or in vivo experiments. All group results are expressed as mean ± SEM,
if not stated otherwise. Comparisons between groups were made using the two-
tailed Student’s t-test or one-way ANOVA and Tukey post-hoc tests for multiple
groups. Statistical signiﬁcance as compared to untreated controls is denoted with *
(P < 0.05), ** (P < 0.01), *** (P < 0.001) in the ﬁgures and ﬁgure legends. Statistical
analysis was performed in Graph Pad PRISM 5.
Data availability. The deep sequencing data from this study have been submitted
to the NCBI Sequence Read Archive under accession number SRP129908. The data
that support the ﬁndings of this study are available from the corresponding author
upon reasonable request.
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